CStone Pharmaceuticals has announced that it will present new clinical advancements at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany, which is scheduled to take place from October 17-21. Key presentations will include the first-in-human Phase Ia data for the novel PD-1/VEGF/CTLA-4 trispecific antibody, CS2009, as well as the design of a global multicenter Phase Ib study for its ROR1-targeting antibody-drug conjugate $(ADC)$, CS5001. These presentations aim to showcase the latest developments from CStone's Pipeline 2.0. The company advises that the forward-looking statements made in the announcement are subject to change based on future developments.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.